<div id="readability-page-1"><p>Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Insmed on May 8 and set a price target of $200.00. The company’s shares closed last Friday at $101.35.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Incyte, and Insmed. According to TipRanks, Willey has an average return of <span>9.7%</span> and a 44.65% success rate on recommended stocks. </p> <p>Insmed has an analyst consensus of Strong Buy, with a price target consensus of $207.79, representing a 105.02% upside. In a report released on May 8, Barclays also maintained a Buy rating on the stock with a $237.00 price target.</p></div>

INSM

<p>Stifel Nicolaus analyst Stephen Willey has maintained a Buy rating on Insmed (INSM) with a price target of $200.00, while the stock closed at $101.35. Willey, who focuses on the Healthcare sector, has an average return of 9.7% and a success rate of 44.65%. Insmed has a Strong Buy consensus with a price target of $207.79, indicating a potential upside of 105.02%. Barclays also supports a Buy rating with a target of $237.00.</p>

Tip Ranks

Insmed

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

VG Health

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares US Pharma

Invesco Dorsey Wright Healthcare Momentum ETF

Stifel Financial

Disc Medicine

Incyte

Barclays

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Insmed (INSM)